Back

Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland

28 August 2022 (15:15 - 16:00)
Organised by:
Congress Presentation Part of: Secondary prevention 2 Secondary Prevention ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Inna Thalmann

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Clinical routines for diabetes screening and treatment in cardiac rehabilitation improves detection and treatment of diabetes mellitus in patients with myocardial infarction
Miss B. Sharad (Malmo, SE)
Abstract Slides
Presentation thumbnail
Impact of antihypertensive medication regimens on blood pressure control in individuals with established coronary heart disease
Doctor S. Brennan (Dublin, IE)
Abstract Slides
Presentation thumbnail
Improved adherence to statins following pictorial intervention. Sub study of visualization of subclinical atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA)
Associate Professor H. Holmberg (Umea, SE)
Abstract Slides
Presentation thumbnail
Effect of in-hospital nurse-led smoking cessation intervention for patients with atherosclerotic cardiovascular disease: a randomised pilot study
Mrs K. Pleym (Drammen, NO)
Abstract Slides
Presentation thumbnail
Does low glycemic index diet superior than routine diet to control blood inflammation state and lipid parameters in patients with coronary artery disease?
Doctor J. Uzokov (Tashkent, UZ)
Abstract Slides

Access the full session

Session thumbnail
Secondary prevention 2

The Event

Event poster

ESC Congress 2022

28 August 2022 15:15 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources